Market Overview

How A Walgreens-AmerisourceBergen Combo Stacks Up Against CVS-Aetna

Share:
How A Walgreens-AmerisourceBergen Combo Stacks Up Against CVS-Aetna
Related WBA
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
Positive Vibes: Bank Results Shift Focus Back To Earnings as Overseas Stocks Rise
Walgreens Boots Alliance's (WBA) CEO Stefano Pessina Credit Suisse Healthcare Conference - Transcript (Seeking Alpha)
Related ABC
75 Biggest Movers From Yesterday
60 Stocks Moving In Tuesday's Mid-Day Session
Tracking Seth Klarman's Baupost Group Holdings - Q3 2018 Update (Seeking Alpha)

Some see Walgreens Boots Alliance Inc (NASDAQ: WBA)’s reported pursuit of AmerisourceBergen Corp. (NYSE: ABC) as a smart defensive play.

The purchase would cut costs in the drug supply chain, increase appeal with pharmacy benefit managers and insurers and strengthen the drugstore operator against rivals like Amazon.com, Inc. (NASDAQ: AMZN), according to CNBC.

But one sell-side analyst is expressing doubt about a deal. 

'It Doesn’t Make Sense'

An acquisition makes sense, considering the recent wave of health care consolidation, but this particular acquisition by this particular buyer would be a “head-scratcher,” said Baird analyst Eric Coldwell. In fact, Coldwell said he is dubious of the veracity of the Wall Street Journal report.

“I like Walgreens and I like ABC,” the analyst told Benzinga. “I have Outperforms on both stocks, but I’m struggling to see the merits of this deal.”

For one, Walgreens has an existing global distribution business and is vertically integrated outside the U.S.

At the same time, the incremental benefits of deepening its AmerisourceBergen relationship relative to the purchase price are unseen.

AmerisourceBergen already supports Walgreens’ general procurement, while Walgreens occupies a seat on the target’s board, owns a 26-percent stake and is the firm’s largest client. Walgreens represented 30 percent of AmerisourceBergen’s revenue last year, and Coldwell said the present arrangement is inexpensive.

“If Walgreens wants to do something innovative with ABC, ABC is going to be all over that,” he said. “They’re going to be happy to do it, happy to work together. I just don’t know what you really get by becoming a vertically integrated distributor in the U.S.”

What Could Go Wrong?

A merger might also fail to stave off the threat of a united CVS Health Corp (NYSE: CVS)-Aetna Inc (NYSE: AET).

“Frankly, I see the CVS-Aetna transaction as high-risk, high reward, whereas the Walgreens-ABC transaction, if it were to come to fruition, I would see as low-risk, low reward,” Coldwell said. “Certainly it would be a lot easier to buy the rest of ABC and integrate it and a lot less risk with external customers or competitors than with CVS-Aetna, a lot less investment that would have to be made over the next decade — but if CVS and Aetna get it right, and that’s an ‘if’ for me, if they get it right, the payoff could be a lot bigger than Walgreens plus ABC.”

By the Baird analyst's assessment, Walgreens would be wise to wait while CVS and Aetna test their model. If their strategy fails, Walgreens could opt out of M&A and be viewed more attractively than its competitor. 

If the model succeeds, the independent, pure-play pharmacy could be an attractive target for United, Humana Inc (NYSE: HUM), Anthem Inc (NYSE: ANTM), CIGNA Corporation (NYSE: CI) or others looking to replicate Aetna’s strategy.

Ownership of ABC may diminish Walgreens’ appeal and preclude this opportunity, Coldwell said. 

“It just seems you’d be locking yourself into a strategy, whereas there might be other options down the road,” Coldwell said.

The Other Options

Those other options are numerous considering Walgreens’ relationship history — the recent Rite Aid Corporation (NYSE: RAD) store purchases; the Walgreens-Prime joint venture for specialty pharmacy; the stake in KKR’s PharMerica; the sale of its infusion business to Madison Dearborn; the partnership with UnitedHealth Group Inc (NYSE: UNH); the leasing of Walgreens walk-in clinics to local health systems; even the FedEx Corporation (NYSE: FDX) collaboration.

“I don’t know how buying ABC makes sense right here right now when there are so many other dynamics in the marketplace,” Coldwell said, noting that Walgreens could instead expand its partnership with FedEx or even collaborate with Amazon.

Haste Makes Waste

The analyst said he is not entirely opposed to a Walgreens-AmerisourceBergen transaction, nor does he consider it “awful.” He’s merely unconvinced that it would be accretive and sees time for careful deliberation.

“I don’t know how ABC could really do anything with anybody else,” he said. “You’re not at risk of losing them, I would think. You already own 26 percent of them. You’re their biggest client. They’re not going anywhere.”

At the time of publication, Walgreens was trading relatively flat while AmerisourceBergen traded up more than 9 percent.

Related Links:

Jefferies: Weakening Generic Drug Prices Putting Pressure On 3 Healthcare Stocks

Prescribing A Pharmacy Trade: Walgreens Vs. CVS Vs. Fred's

Photo by Theopolisme/Wikimedia. 

Latest Ratings for WBA

DateFirmActionFromTo
Oct 2018BarclaysMaintainsEqual-WeightEqual-Weight
Oct 2018BairdMaintainsNeutralNeutral
Oct 2018CitigroupMaintainsNeutralNeutral

View More Analyst Ratings for WBA
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Rumors M&A Top Stories Exclusives Analyst Ratings Best of Benzinga

 

Related Articles (ABC + AET)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AMTDMorgan StanleyUpgrades65.0
APOMorgan StanleyDowngrades34.0
ARMKBairdUpgrades44.0
CGMorgan StanleyDowngrades23.0
EIXEdward JonesDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Bank Of America Impressed With Americold's Market Positioning, High Development Returns

Mid-Afternoon Market Update: Chegg Surges After Strong Q4 Results; Dare Bioscience Shares Slide